Repatriation Medical Authority - Notice of Investigation - Diabetes Mellitus - focussed

Overview

The Veterans' Entitlements Act 1986 (VEA) was enacted to provide for the payment of pensions and other benefits to veterans, their families, and dependants. This Act aims to address the gap in recognising and compensating the health impacts faced by veterans and their families, including the long-term effects of their service on physical and mental health. The Repatriation Medical Authority (the Authority), established under the VEA, is responsible for managing the assessment and payment of benefits. The Authority has announced an investigation into the potential link between infection with Coxsackie B virus and diabetes mellitus as a factor under Statement of Principles Instrument No. 48 of 2020 concerning diabetes mellitus. This investigation invites relevant parties, including eligible claimants, representatives of veterans and their families, and experts in relevant fields, to submit written submissions by 23 March 2021, as part of its efforts to provide comprehensive support and recognition to affected individuals.

Scope and Application

The Repatriation Medical Authority (the Authority) under section 196G of the Veterans' Entitlements Act 1986 (VEA) has announced its intention to conduct an investigation into the relationship between Coxsackie B virus infection and diabetes mellitus, in line with Statement of Principles Instrument No. 48 of 2020. The investigation aims to examine this connection within the scope of the Act and welcomes written submissions from various stakeholders, including eligible claimants under Parts II or IV of the VEA, those eligible for compensation under the Military Rehabilitation and Compensation Act 2004, organisations representing veterans and their dependents, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and experts relevant to the investigation. The Authority has specified that all submissions must be submitted in writing by 23 March 2021, either electronically via the RMA website, by email, or by post, with guidelines and further assistance available through the RMA Secretariat. This investigation applies to those with direct interests or expertise in the fields of veterans' entitlements and medical conditions relevant to the Act. The scope of the investigation is limited to the specified geographic jurisdiction under the VEA and does not extend beyond the national boundaries of Australia. The Act does not explicitly mention any exclusions, exemptions, or thresholds that would restrict the application of this investigation. However, it is worth noting that the investigation may be subject to further regulation or clarification through subordinate instruments issued by the Authority.

Key Provisions

The notice under section 196G of the Veterans' Entitlements Act 1986 (VEA) announces an investigation by the Repatriation Medical Authority (the Authority) into the potential link between Coxsackie B virus infection and diabetes mellitus. This investigation is to be conducted in the context of Statement of Principles Instrument No. 48 of 2020, which pertains to diabetes mellitus. The Authority is inviting written submissions from various stakeholders, including those eligible to make claims under the VEA or the Military Rehabilitation and Compensation Act 2004 (MRCA), organisations representing veterans and other eligible groups, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and individuals with relevant expertise. The first meeting for this investigation is scheduled for 7 April 2021, and submissions can be made electronically via the RMA website, by email, or by post. The deadline for submissions is 23 March 2021, and the RMA Submission Guidelines are available online for those needing guidance. The obligations imposed by the notice include the requirement for eligible individuals and organisations to submit written statements by the specified deadline. This submission process aims to gather comprehensive information and perspectives from those directly affected by or knowledgeable about the potential link between Coxsackie B virus infection and diabetes mellitus. The Authority encourages the use of its website for electronic submissions, ensuring a streamlined and accessible process. Submissions can also be made via email or post, providing flexibility for those who may not have easy access to the internet. The RMA Secretariat is available for any further assistance required during the submission process. The notice does not explicitly outline offences, penalties, or civil/criminal consequences for failing to comply with the submission requirements. However, the mandatory nature of the submissions suggests that non-compliance might result in missed opportunities for input into the investigation, potentially impacting the comprehensiveness and fairness of the investigation's findings. While the notice does not detail specific penalties for non-compliance, the importance of the investigation and the detailed submission guidelines imply a strong expectation of participation from the invited stakeholders.